As of 2025-06-18, the EV/EBITDA ratio of Intellia Therapeutics Inc (NTLA) is -1.63. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. NTLA's latest enterprise value is 865.42 mil USD. NTLA's TTM EBITDA according to its financial statements is -530.80 mil USD. Dividing these 2 quantities gives us the above NTLA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.3x - 13.7x | 12.6x |
| Forward P/E multiples | 16.6x - 38.1x | 25.8x |
| Fair Price | (84.05) - (69.08) | (97.17) |
| Upside | -977.3% - -821.1% | -1114.3% |
| Date | EV/EBITDA |
| 2025-06-17 | -1.63 |
| 2025-06-16 | -1.51 |
| 2025-06-13 | -1.38 |
| 2025-06-12 | -1.39 |
| 2025-06-11 | -1.39 |
| 2025-06-10 | -1.41 |
| 2025-06-09 | -1.38 |
| 2025-06-06 | -1.34 |
| 2025-06-05 | -1.24 |
| 2025-06-04 | -1.26 |
| 2025-06-03 | -1.26 |
| 2025-06-02 | -1.16 |
| 2025-05-30 | -1.10 |
| 2025-05-29 | -1.21 |
| 2025-05-28 | -1.65 |
| 2025-05-27 | -1.58 |
| 2025-05-23 | -1.55 |
| 2025-05-22 | -1.61 |
| 2025-05-21 | -1.56 |
| 2025-05-20 | -1.65 |
| 2025-05-19 | -1.53 |
| 2025-05-16 | -1.42 |
| 2025-05-15 | -1.34 |
| 2025-05-14 | -1.30 |
| 2025-05-13 | -1.38 |
| 2025-05-12 | -1.43 |
| 2025-05-09 | -1.35 |
| 2025-05-08 | -1.38 |
| 2025-05-07 | -1.18 |
| 2025-05-06 | -1.18 |
| 2025-05-05 | -1.41 |
| 2025-05-02 | -1.49 |
| 2025-05-01 | -1.45 |
| 2025-04-30 | -1.49 |
| 2025-04-29 | -1.36 |
| 2025-04-28 | -1.42 |
| 2025-04-25 | -1.38 |
| 2025-04-24 | -1.36 |
| 2025-04-23 | -1.34 |
| 2025-04-22 | -1.38 |
| 2025-04-21 | -1.31 |
| 2025-04-17 | -1.17 |
| 2025-04-16 | -1.10 |
| 2025-04-15 | -1.20 |
| 2025-04-14 | -1.22 |
| 2025-04-11 | -1.21 |
| 2025-04-10 | -1.08 |
| 2025-04-09 | -1.14 |
| 2025-04-08 | -0.99 |
| 2025-04-07 | -1.04 |